New hope for Hard-to-Treat lymphoma: phase 3 trial launches
NCT ID NCT07011056
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial tests a new drug called purinostat mesylate against an existing drug, selinexor, in 390 adults with relapsed or refractory diffuse large B-cell lymphoma. Participants receive either purinostat mesylate by infusion or selinexor by mouth. The study aims to see which drug works better at shrinking tumors and improving survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- purinostat mesylate
- What this could lead to
- If it works, this could offer a new treatment option for people with hard-to-treat diffuse large B-cell lymphoma who have not responded to other therapies.
- What could go wrong
- This is a phase 3 trial, but it compares a new drug to another existing drug, so the benefit may be modest. Side effects are possible, and the drug may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT AND REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital Sichuan University
RECRUITINGChengdu, Sichuan, 610200, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••